Elicio Therapeutics presents late-breaking Phase 2 AMPLIFY-7P results at ESMO Congress 2026

Elicio Therapeutics presented late-breaking Phase 2 AMPLIFY-7P results at ESMO Congress 2026. Multiple pre-specified subgroup analyses favored camupepimut, including patients with and without detectable baseline ctDNA, with encouraging disease-free survival outcomes observed in both ctDNA-negative and ctDNA-positive patients.

Detected & updated continuously · Source: Nebula